In humans, remifentanil anesthesia enhances nociceptive sensitization in the postoperative period. We hypothesized that activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and the expression of c-Fos, prodynorphin (mRNA), and dynorphin in the spinal cord could participate in the molecular mechanisms underlying postoperative opioid-induced sensitization. In a mouse model of incisional pain, we evaluated thermal (Hargreaves test) and mechanical (von Frey) hyperalgesia during the first 21 postoperative days. Moreover, prodynorphin (mRNA, real-time polymerase chain reaction), dynorphin (enzymatic immunoassay), c-Fos expression, and ERK1/2 phosphorylation (both by immunohistochemistry) in the lumbar spinal cord were assessed. Surgery performed under remifentanil anesthesia induced a maximal decrease in nociceptive thresholds between 4 h and 2 days postoperatively (p Ͻ 0.001) that lasted 10 to 14 days compared with noninjured animals. In the same experimental conditions, a significant increase in prodynorphin mRNA expression (at 2 and 4 days) followed by a sustained increase of dynorphin (days 2 to 10) in the spinal cord was observed. We also identified an early expression of c-Fos immunoreactivity in the superficial laminae of the dorsal horn of the spinal cord (peak at 4 h; p Ͻ 0.001), together with a partial activation of ERK1/2 (4 h; p Ͻ 0.001). These findings suggest that activated ERK1/2 could induce c-Fos expression and trigger the transcription of prodynorphin in the spinal cord. This in turn would result in long-lasting increased levels of dynorphin that, in our model, could participate in the persistence of pain but not in the manifestation of first pain.In humans, exposure to -opioid receptor agonists during anesthesia induces delayed hyperalgesia, increasing pain and analgesic requirements in the postoperative period (Angst and Clark, 2006). The pronociceptive effects of opioids have also been reported in human volunteers and in animal models (Li et al., 2001;Angst et al., 2003). In a mouse model of postoperative pain, we have shown that postincisional pain is enhanced when the ultra-short-acting -opioid receptor agonist remifentanil is administered during anesthesia (Célé rier et al., 2006;Cabañ ero et al., 2009b). Remifentanil is commonly used in clinical practice to provide analgesia during surgery, although it has been associated with hyperalgesia in the immediate postoperative period (Angst and Clark, 2006;Joly et al., 2005).The mechanisms and signal transduction pathways that mediate pain sensitization after opioid administration are not well known. Multiple central and peripheral pathways and mechanisms have been implicated, including C-fiber sensitization, protein kinase C, the nitric oxide system, N-methyl-D-aspartate (NMDA) receptors, mitogen-activated protein kinases (MAPKs) and spinal dynorphin, among others (Angst and Clark, 2006). It has also been shown that down-regulation of ␦-opioid receptor mRNA in the dorsal root ganglia contributes to remifentanil and surgery-i...